NewLink Genetics (NLNK) Given a $26.00 Price Target at Cantor Fitzgerald

Cantor Fitzgerald set a $26.00 price target on NewLink Genetics (NASDAQ:NLNK) in a report released on Monday. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other research firms have also recently weighed in on NLNK. Zacks Investment Research cut NewLink Genetics from a buy rating to a hold rating in a research report on Thursday, January 4th. Stifel Nicolaus increased their price objective on NewLink Genetics from $25.00 to $29.00 and gave the company a buy rating in a research report on Friday, November 3rd. Jefferies Group reduced their price objective on NewLink Genetics from $26.00 to $25.00 and set a buy rating for the company in a research report on Friday, November 3rd. Bank of America initiated coverage on NewLink Genetics in a research report on Friday, October 13th. They issued a buy rating and a $22.00 price objective for the company. Finally, ValuEngine cut NewLink Genetics from a sell rating to a strong sell rating in a research report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $23.29.

NewLink Genetics (NASDAQ NLNK) traded up $0.14 on Monday, hitting $8.58. The stock had a trading volume of 739,632 shares, compared to its average volume of 1,120,270. NewLink Genetics has a 12 month low of $5.90 and a 12 month high of $25.17. The company has a market capitalization of $310.78, a PE ratio of -3.52 and a beta of 1.10.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company raised its stake in shares of NewLink Genetics by 3.0% in the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 556 shares in the last quarter. Advisor Group Inc. raised its stake in shares of NewLink Genetics by 3.4% in the second quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 600 shares in the last quarter. First Trust Advisors LP raised its stake in shares of NewLink Genetics by 11.1% in the second quarter. First Trust Advisors LP now owns 28,598 shares of the biotechnology company’s stock valued at $210,000 after purchasing an additional 2,859 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of NewLink Genetics by 1.8% in the second quarter. Wells Fargo & Company MN now owns 165,791 shares of the biotechnology company’s stock valued at $1,219,000 after purchasing an additional 2,865 shares in the last quarter. Finally, State Street Corp raised its stake in shares of NewLink Genetics by 1.2% in the second quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock valued at $2,875,000 after purchasing an additional 4,630 shares in the last quarter. Institutional investors and hedge funds own 52.63% of the company’s stock.

WARNING: “NewLink Genetics (NLNK) Given a $26.00 Price Target at Cantor Fitzgerald” was first posted by Week Herald and is owned by of Week Herald. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://weekherald.com/2018/01/12/newlink-genetics-nlnk-given-a-26-00-price-target-at-cantor-fitzgerald.html.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply